tetano
Editor, Senior Moderator
NPJ Vaccines
. 2020 Jul 23;5(1):64.
doi: 10.1038/s41541-020-00211-5.
Specific targeting of IL-1β activity to CD8 [SUP]+[/SUP] T cells allows for safe use as a vaccine adjuvant
Bram Van Den Eeckhout[SUP] 1 2 [/SUP], Lien Van Hoecke[SUP] 1 3 [/SUP], Elianne Burg[SUP] 1 2 [/SUP], Sandra Van Lint[SUP] 1 2 [/SUP], Frank Peelman[SUP] 1 2 [/SUP], Niko Kley[SUP] 4 [/SUP], Gilles Uz?[SUP] 5 [/SUP], Xavier Saelens[SUP] 1 3 6 [/SUP], Jan Tavernier[SUP] #[/SUP][SUP] 7 8 9 [/SUP], Sarah Gerlo[SUP] #[/SUP][SUP] 10 11 [/SUP]
Affiliations
Abstract
Annual administration and reformulation of influenza vaccines is required for protection against seasonal infections. However, the induction of strong and long-lasting T cells is critical to reach broad and potentially lifelong antiviral immunity. The NLRP3 inflammasome and its product interleukin-1β (IL-1β) are pivotal mediators of cellular immune responses to influenza, yet, overactivation of these systems leads to side effects, which hamper clinical applications. Here, we present a bypass around these toxicities by targeting the activity of IL-1β to CD8[SUP]+[/SUP] T cells. Using this approach, we demonstrate safe inclusion of IL-1β as an adjuvant in vaccination strategies, leading to full protection of mice against a high influenza virus challenge dose by raising potent T cell responses. In conclusion, this paper proposes a class of IL-1β-based vaccine adjuvants and also provides further insight in the mechanics of cellular immune responses driven by IL-1β.
. 2020 Jul 23;5(1):64.
doi: 10.1038/s41541-020-00211-5.
Specific targeting of IL-1β activity to CD8 [SUP]+[/SUP] T cells allows for safe use as a vaccine adjuvant
Bram Van Den Eeckhout[SUP] 1 2 [/SUP], Lien Van Hoecke[SUP] 1 3 [/SUP], Elianne Burg[SUP] 1 2 [/SUP], Sandra Van Lint[SUP] 1 2 [/SUP], Frank Peelman[SUP] 1 2 [/SUP], Niko Kley[SUP] 4 [/SUP], Gilles Uz?[SUP] 5 [/SUP], Xavier Saelens[SUP] 1 3 6 [/SUP], Jan Tavernier[SUP] #[/SUP][SUP] 7 8 9 [/SUP], Sarah Gerlo[SUP] #[/SUP][SUP] 10 11 [/SUP]
Affiliations
- PMID: 33574336
- DOI: 10.1038/s41541-020-00211-5
Abstract
Annual administration and reformulation of influenza vaccines is required for protection against seasonal infections. However, the induction of strong and long-lasting T cells is critical to reach broad and potentially lifelong antiviral immunity. The NLRP3 inflammasome and its product interleukin-1β (IL-1β) are pivotal mediators of cellular immune responses to influenza, yet, overactivation of these systems leads to side effects, which hamper clinical applications. Here, we present a bypass around these toxicities by targeting the activity of IL-1β to CD8[SUP]+[/SUP] T cells. Using this approach, we demonstrate safe inclusion of IL-1β as an adjuvant in vaccination strategies, leading to full protection of mice against a high influenza virus challenge dose by raising potent T cell responses. In conclusion, this paper proposes a class of IL-1β-based vaccine adjuvants and also provides further insight in the mechanics of cellular immune responses driven by IL-1β.